ES2275012T3 - Intermedios para la sintesis de agonista lhrh, proceso para su produccion, y proceso para la produccion del antagonista lhrh. - Google Patents
Intermedios para la sintesis de agonista lhrh, proceso para su produccion, y proceso para la produccion del antagonista lhrh. Download PDFInfo
- Publication number
- ES2275012T3 ES2275012T3 ES02781699T ES02781699T ES2275012T3 ES 2275012 T3 ES2275012 T3 ES 2275012T3 ES 02781699 T ES02781699 T ES 02781699T ES 02781699 T ES02781699 T ES 02781699T ES 2275012 T3 ES2275012 T3 ES 2275012T3
- Authority
- ES
- Spain
- Prior art keywords
- boc
- 4clphe
- 3pal
- 2nal
- lys
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000000034 method Methods 0.000 title claims description 23
- 230000008569 process Effects 0.000 title claims description 19
- 229940124041 Luteinizing hormone releasing hormone (LHRH) antagonist Drugs 0.000 title claims description 11
- 239000002474 gonadorelin antagonist Substances 0.000 title claims description 8
- 238000004519 manufacturing process Methods 0.000 title abstract description 9
- XLXSAKCOAKORKW-UHFFFAOYSA-N gonadorelin Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 XLXSAKCOAKORKW-UHFFFAOYSA-N 0.000 title description 12
- 230000015572 biosynthetic process Effects 0.000 title description 11
- 238000003786 synthesis reaction Methods 0.000 title description 9
- 101000904173 Homo sapiens Progonadoliberin-1 Proteins 0.000 title description 8
- 102100024028 Progonadoliberin-1 Human genes 0.000 title description 8
- 101000996723 Sus scrofa Gonadotropin-releasing hormone receptor Proteins 0.000 title description 8
- 239000000543 intermediate Substances 0.000 title description 8
- 150000003839 salts Chemical class 0.000 claims abstract description 5
- URKWHOVNPHQQTM-OAHLLOKOSA-N (2r)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-3-naphthalen-2-ylpropanoic acid Chemical compound C1=CC=CC2=CC(C[C@@H](NC(=O)OC(C)(C)C)C(O)=O)=CC=C21 URKWHOVNPHQQTM-OAHLLOKOSA-N 0.000 claims abstract description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 30
- 150000001413 amino acids Chemical class 0.000 claims description 19
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 5
- 230000001681 protective effect Effects 0.000 claims description 5
- 125000003277 amino group Chemical group 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 125000006239 protecting group Chemical group 0.000 claims description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims 2
- 239000000203 mixture Substances 0.000 description 30
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 20
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 18
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 18
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 16
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 15
- 239000000047 product Substances 0.000 description 13
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 238000004128 high performance liquid chromatography Methods 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- 238000001556 precipitation Methods 0.000 description 6
- 230000021736 acetylation Effects 0.000 description 5
- 238000006640 acetylation reaction Methods 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 229960004592 isopropanol Drugs 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- VIHYIVKEECZGOU-UHFFFAOYSA-N N-acetylimidazole Chemical compound CC(=O)N1C=CN=C1 VIHYIVKEECZGOU-UHFFFAOYSA-N 0.000 description 4
- 239000005557 antagonist Substances 0.000 description 4
- 238000010511 deprotection reaction Methods 0.000 description 4
- 229940088597 hormone Drugs 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 3
- 102000009151 Luteinizing Hormone Human genes 0.000 description 3
- 108010073521 Luteinizing Hormone Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- -1 allyl ester Chemical class 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 229940040129 luteinizing hormone Drugs 0.000 description 3
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 230000001012 protector Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 201000009273 Endometriosis Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 230000006340 racemization Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000007127 saponification reaction Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/23—Luteinising hormone-releasing hormone [LHRH]; Related peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/02—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Endocrinology (AREA)
- Analytical Chemistry (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0104463 | 2001-12-29 | ||
| SE0104463A SE0104463D0 (sv) | 2001-12-29 | 2001-12-29 | Mellanprodukter för syntes af LHRH-antagonister, sätt att framställa dem och sätt för framställning av LHRH-antagonister |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2275012T3 true ES2275012T3 (es) | 2007-06-01 |
Family
ID=20286557
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES02781699T Expired - Lifetime ES2275012T3 (es) | 2001-12-29 | 2002-12-23 | Intermedios para la sintesis de agonista lhrh, proceso para su produccion, y proceso para la produccion del antagonista lhrh. |
| ES05025717T Expired - Lifetime ES2296050T3 (es) | 2001-12-29 | 2002-12-23 | Productos intermedios para sintesis de antagonistas de lhrh, procedimiento para su produccion y procedimiento para la produccion de antagonistas de lhrh. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES05025717T Expired - Lifetime ES2296050T3 (es) | 2001-12-29 | 2002-12-23 | Productos intermedios para sintesis de antagonistas de lhrh, procedimiento para su produccion y procedimiento para la produccion de antagonistas de lhrh. |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US20050124788A1 (enExample) |
| EP (2) | EP1465917B1 (enExample) |
| JP (1) | JP4272529B2 (enExample) |
| KR (1) | KR100844520B1 (enExample) |
| CN (1) | CN1304417C (enExample) |
| AT (2) | ATE371666T1 (enExample) |
| AU (1) | AU2002348749B2 (enExample) |
| CA (1) | CA2471723C (enExample) |
| CY (2) | CY1107580T1 (enExample) |
| DE (2) | DE60215544T2 (enExample) |
| DK (2) | DK1465917T3 (enExample) |
| ES (2) | ES2275012T3 (enExample) |
| IL (2) | IL162788A0 (enExample) |
| NO (1) | NO330129B1 (enExample) |
| NZ (1) | NZ534245A (enExample) |
| PT (2) | PT1465917E (enExample) |
| RU (1) | RU2307125C2 (enExample) |
| SE (1) | SE0104463D0 (enExample) |
| SI (1) | SI1630169T1 (enExample) |
| WO (1) | WO2003055902A1 (enExample) |
| ZA (1) | ZA200405136B (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4407322B2 (ja) | 2004-03-09 | 2010-02-03 | 味の素株式会社 | ペプチドの製造方法 |
| CN101037472B (zh) * | 2006-03-14 | 2013-03-27 | 中国人民解放军军事医学科学院毒物药物研究所 | 具有低组胺释放作用的促黄体生成素释放激素拮抗剂 |
| TWI539959B (zh) | 2008-02-11 | 2016-07-01 | 菲瑞茵國際中心股份有限公司 | 治療轉移階段攝護腺癌的方法 |
| EP2447276A1 (en) * | 2010-10-27 | 2012-05-02 | Ferring B.V. | Process for the manufacture of Degarelix and its intermediates |
| DK2632934T3 (en) | 2010-10-27 | 2017-01-23 | Ferring Bv | Process for the preparation of Degarelix and its intermediates |
| SI2854831T1 (sl) | 2012-06-01 | 2024-11-29 | Ferring B.V. | Izdelava degareliksa |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4098777A (en) * | 1977-03-14 | 1978-07-04 | Merck & Co., Inc. | Process for the preparation of pyroglutamyl-Ala-Lys-Ser-Gln-Gly-Gly-Ser-Asn |
| SU1623166A1 (ru) * | 1989-04-03 | 1994-02-15 | Институт биоорганической химии АН БССР | Нейтропептиды, обладающие поведенческой активностью |
| US5225598A (en) * | 1990-03-30 | 1993-07-06 | Union Carbide Chemicals & Plastics Technology Corporation | Selective production of linear pentaethylenehexamine and hydroxyethyldiethylenetriamine |
| EP0540626A1 (en) * | 1990-07-24 | 1993-05-12 | Eastman Chemical Company | Process for synthesizing peptides |
| US5710246A (en) * | 1996-03-19 | 1998-01-20 | Abbott Laboratories | Process for intermediates for the synthesis of LHRH antagonists |
| US6235734B1 (en) * | 1996-10-30 | 2001-05-22 | Pfizer Inc | Pyridone-fused azabicyclic- or cytisine derivatives, their preparation and their use in addiction therapy |
| US5968895A (en) * | 1996-12-11 | 1999-10-19 | Praecis Pharmaceuticals, Inc. | Pharmaceutical formulations for sustained drug delivery |
| DE19941248A1 (de) | 1998-09-01 | 2000-03-02 | Asta Medica Ag | Peptide mit N-substituierten Glycingruppen sowie diese enthaltende Arzneimittel zur Behandlung hormonabhängiger Tumore |
-
2001
- 2001-12-29 SE SE0104463A patent/SE0104463D0/xx unknown
-
2002
- 2002-12-23 IL IL16278802A patent/IL162788A0/xx unknown
- 2002-12-23 US US10/500,047 patent/US20050124788A1/en not_active Abandoned
- 2002-12-23 DK DK02781699T patent/DK1465917T3/da active
- 2002-12-23 AT AT05025717T patent/ATE371666T1/de active
- 2002-12-23 PT PT02781699T patent/PT1465917E/pt unknown
- 2002-12-23 NZ NZ534245A patent/NZ534245A/en not_active IP Right Cessation
- 2002-12-23 CN CNB028283813A patent/CN1304417C/zh not_active Expired - Fee Related
- 2002-12-23 ES ES02781699T patent/ES2275012T3/es not_active Expired - Lifetime
- 2002-12-23 ES ES05025717T patent/ES2296050T3/es not_active Expired - Lifetime
- 2002-12-23 WO PCT/IB2002/005583 patent/WO2003055902A1/en not_active Ceased
- 2002-12-23 PT PT05025717T patent/PT1630169E/pt unknown
- 2002-12-23 SI SI200230642T patent/SI1630169T1/sl unknown
- 2002-12-23 AU AU2002348749A patent/AU2002348749B2/en not_active Ceased
- 2002-12-23 DE DE60215544T patent/DE60215544T2/de not_active Expired - Lifetime
- 2002-12-23 CA CA2471723A patent/CA2471723C/en not_active Expired - Fee Related
- 2002-12-23 EP EP02781699A patent/EP1465917B1/en not_active Expired - Lifetime
- 2002-12-23 AT AT02781699T patent/ATE342913T1/de active
- 2002-12-23 KR KR1020047010267A patent/KR100844520B1/ko not_active Expired - Fee Related
- 2002-12-23 JP JP2003556432A patent/JP4272529B2/ja not_active Expired - Fee Related
- 2002-12-23 RU RU2004119964/04A patent/RU2307125C2/ru not_active IP Right Cessation
- 2002-12-23 EP EP05025717A patent/EP1630169B1/en not_active Expired - Lifetime
- 2002-12-23 DE DE60222189T patent/DE60222189T2/de not_active Expired - Lifetime
- 2002-12-23 DK DK05025717T patent/DK1630169T3/da active
-
2004
- 2004-06-28 ZA ZA2004/05136A patent/ZA200405136B/en unknown
- 2004-06-29 IL IL162788A patent/IL162788A/en not_active IP Right Cessation
- 2004-07-16 NO NO20043047A patent/NO330129B1/no not_active IP Right Cessation
-
2007
- 2007-01-18 CY CY20071100070T patent/CY1107580T1/el unknown
- 2007-11-27 CY CY20071101513T patent/CY1107025T1/el unknown
-
2008
- 2008-08-12 US US12/189,925 patent/US8173770B2/en not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8828938B2 (en) | Method for the manufacture of degarelix | |
| US8173770B2 (en) | Intermediates for LHRH antagonist synthesis, process for the production, and process for LHRH antagonist production | |
| EP0473411A1 (en) | Xanthenylamide handle for use in peptide synthesis and methods of producing said handle and support incorporating it | |
| KR100203548B1 (ko) | 고체상 합성에 의한 펩티드의 제조방법 | |
| JPH08311095A (ja) | ペプチドの合成方法 | |
| PL91030B1 (enExample) | ||
| JPH049800B2 (enExample) | ||
| JP2005255556A (ja) | ペプチドの製造方法 | |
| JPH07316193A (ja) | ペプチド誘導体およびその用途 | |
| JP2002530428A (ja) | Ｌ−プロリル−Ｌ−ｍ−サルコリシル−Ｌ−ｐ−フルオロフェニルアラニンとその誘導体の製造方法 | |
| HK1075052B (en) | Intermediates for lhrh antagonist synthesis, process for their production, and process for lhrh antagonist production |